Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P21554 (
cannabinoid receptor
)
3,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Anandamide has been identified in porcine brain as an endogenous
cannabinoid receptor
ligand and is believed to be a counterpart to the psychoactive component of marijuana, delta 9-tetrahydrocannabinol (delta 9-THC). Here we report that anandamide directly inhibits (IC50, 2.7 muM) Shaker-related
Kv1.2
K+ channels that are found ubiquitously in the mammalian brain. Delta 9-THC also inhibited
Kv1.2
channels with comparable potency (IC50, 2.4 muM), as did several N-acyl-ethanolamides with
cannabinoid receptor
binding activity. Potassium current inhibition occurred through a pertussis toxin-insensitive mechanism and was not prevented by the
cannabinoid receptor
antagonist SR141716A. Utilizing excised patches of
Kv1.2
channel-rich membrane as a rapid and sensitive bioassay, we found that phospholipase D stimulated the release of an endogenous anandamide-like K+ channel blocker from rat brain slices. Structure-activity studies were consistent with the possibility that the released blocker was either anandamide or another N-acyl-ethanolamide.
...
PMID:Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. 893 28